Here, we consider an alternative approach for patients in which at least one of the PTEN alleles is wild type (PHTS and cancer patients), and propose PTEN reactivation by the modulation of post-translational modifications as a mechanism to reduce cellular PIP3 levels. This evidence concerns the gene PTEN and cancer.